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Table S1. 1H and 13C NMR data for 1-3.
1 (CD3OD) 1 ((CD3)2SO) 2 (CD3OD) 3 (CD3OD)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.29 m, 1.7 m 22.0 CH2 2.22 m, 
2.64 brq (13.6)
22.2 CH2 1.29 brq (13.2), 
2.35 brd (13.0)
21.9 CH2
2 1.7 m, 2.19 m 33.9 CH 1.36 d (6.8), 2.22 m 33.0 CH2 1.40-1.46 m, 
2.09-2.16 m
30.3 CH2
3 4.24 dd (10.9, 6.5) 71.4 CH 4.07 m 4.11 dd (10.7, 4.2) 66.4 CH 3.87 dd (11.5, 5.2) 72.8 CH
4 - 87.1 Cq - 54.3 Cq - 84.107 Cq
5 - 43.8 Cq - 63.6 Cq - 49.4 Cq
6 - 107.8 Cq - 206.2 Cq - 110.0 Cq
7 2.03 m, 
2.27 dd (14.1, 12.9)
35.2 CH2 2.28 dd (15.0, 2.7), 
2.72 brt (14.6)
46.2 CH2 1.40-1.46 m, 
2.09-2.16 m
35.8 or 36.0 CH2
8 1.96 m 37.6 CH 1.8 m 1.83 m 42.9 CH 2.21 m 37.2 CH
9 - 51.4 Cq - 53.6 Cq - 48.5 Cq
10 1.89 d (11.2) 47.1 CH 2.22 m 54.3 CH 2.24-2.48 m 43.6 CH
11 2.49 m 42.9 CH2 1.93 dd (12.5, 11.0), 
2.34 dd (13.2, 6.8)
44.2 CH2 2.09-2.16 m 33.0 or 35.3 CH2
12 5.46 t (8.6) 73.5 CH 5.25 brdd, (9.8, 7.1) 71.2 CH 4.85 brd (9.7) 63.7 CH
13 - 126.3 Cq - 124.8 Cq - 130.1 Cq
14 6.47 brs 109.1 CH 6.52 brs 6.41 m 108.8 CH 6.42 m 108.4 CH
15 7.54 brs 145.6 CH 7.72 brs 7.43 m 143.8 7.40 m 143.9 CH
16 7.61 brs 141.8 CH 7.83 brs 7.42 m 139.6 CH 7.39 m 138.7 CH
17 1.08 d (6.8) 16.1 CH3 1.00 d (6.7) 1.03 d (6.7) 15.6 CH3 0.93 d (6.2) 16.6 CH3
18 3.87 d (10.0), 
4.39 d (10.0)
58.3 CH2 4.31 d (9.8), 
3.69 d (9.8)
2.81 d (5.3), 
3.14 d (5.3)
43.676 CH2 3.90 brd (10.9), 
4.45 m
75.8 CH2
19 3.93 d (10.2),
4.82 d (10.2)




64.1 CH2 4.45 m, 
4.68 brd (12.5)
66.4 CH2
20 - 179.3 Cq 5.54 s 99.7 CH - 172.5 Cq
MeC(OR)3 1.41 s 23.9 CH3
MeC(OR)3 - 107.7 Cq
HO-3 5.23 d (5.0)
MeCO2-19 2.07 s 21.1 CH3
MeCO2-19 - 171.2 Cq
MeO-6 3.40 s 48.9 CH3
aOnly selected peaks shown
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Table S2. 1H and 13C NMR data for 4-7.
4 (CD3OD) 5 (CD3OD) 6 (CD3OD) 7 (CD3OD)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.64 m, 2.3 m 29.9 CH2 1.51 brq (11.3), 
2.30 m
23.2 CH2 1.65 m, 2.39 m 22.2 CH2 1.3 m, 2.45 m 22.8 CH2
2 1.66 m, 2.01 m 21.6 CH2 1.67 brq (11.3), 
2.14 m
29.0 CH2 1.65 m, 2.01 m 31.3 CH2 1.45 m, 2.05 m 32.8 CH2
3 4.41 m 60.5 CH 5.59 m 64.7 CH 4.41 m 61.6 CH 3.83 dd (11.6, 5.9) 73.4 CH
4 - 128.5 Cq - 133.9 Cq - 133.0 Cq - 85.6 Cq
5 - 163.0 Cq - 162.9 Cq - 162.4 Cq - 49.7 Cq
6 - 102.4 Cq - 103.5 Cq - 105.8 Cq - 108.2 Cq
7 2.2 m (0.5 H), 2.3 m (0.5 
H), 2.4 m (0.5 H), 2.6 m 
(0.5 H)
39.9 CH2 2.30 m
2.91 m
37 CH2 2.18 m,
2.28 t (9.7)
40.8 CH2 1.48 m, 2.25 m 36.3 CH2
8 2.2 m 36.1 CH 2.37 m 41.7 CH 2.18 m 37.0 CH 2.27 m 34.9 CH
9 - 54.0 Cq 56.1 Cq - 55.2 Cq 50.2 Cq
10 2.85 m 39.9 CH 1.91 m 39.2 CH 2.85 t (8.3) 41.4 CH 43.9 CH
11 2.56 dd (14.2, 8.7, 0.5 H), 
2.57 dd (13.6, 8.5, 0.5 H), 
2.73 dd (14.3, 8.7, 1.0 H)
40.2 CH2 2.51 dd (13.9, 9.0), 
2.74 dd (14.1, 8.2)
40.4 CH2 2.56 dd (14.4, 8.5), 
2.73 dd (14.3, 8.8)
40.7 CH2 1.6 m, 2.25 m 41.3 CH2
12 5.60 t (8.6, 0.5 H), 5.61 t 
(8.6, 0.5 H)
72.3 CH 5.53 dd (8.6, 7.6) 74.1 CH 5.60 t (8.6) 74.0 CH 4.6 m 64.0 CH
13 - 124.7 Cq - 126.5 Cq - 126.5 Cq - 108.1 Cq
14 6.49 m 107.9 CH 6.52 m 109.2 CH 6.49 m 109.2 CH 7.17 m 146.6 CH
15 7.54 d (1.7, 0.5 H), 
7.55 d (1.8, 0.5 H)
139.6 CH 7.56 m 145.7 CH 7.55 m 145.6 CH 5.88 m 99.0 CH
16 7.61 m 144.3 CH 7.65 m 141.8 CH 7.62 m 141.5 CH - 172.2 Cq
17 1.00 d (6.4, 1.5 H), 
1.01 d (6.4, 1.5 H)
16.4 CH3 1.17 d (6.9) 16.8 CH3 1.00 d (6.4) 16.9 CH3 1.00 d (6.4) 16.5 CH3
18 - 170.1 Cq - 179 Cq 170.5 Cq 3.97 d (10.4), 
4.35 d (10.4)
75.8 CH2
19 4.58 d (12), 4.64 d (12) 68.2 CH2
20 - 176.4 Cq - 178.3 Cq - 178.6 Cq - 174.6 Cq
MeCO2-6 2.05 s 20.9 CH3
MeCO2-6 172.0 Cq
MeO-6 3.19 s 51.0 CH3
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Table S3. 1H and 13C NMR data for 8-11.
8 (CD3OD) 9 (CD3OD) 10 (CD3OD) 11 (CDCl3)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.7 m, 2.1 m 21.9 CH2 1.79 m, 2.15 m 22.4 CH2 1.3 m, 2.39 m 22.7 CH2 1.95 m, 1.99 m 23.2 CH2
2 2.2 m, 1.4 m 35.1 or 35.2 
CH2
1.35 m, 2.10 m 34.4 CH2 1.4 m, 2.03 m 32.8 CH2 1.41 brdq (2.9, 9.3), 
2.15 m
30.3 CH2
3 4.00 m 66.5 CH 4.00 brdd (11.5, 4.0) 66.64 or
66.55 CH
3.83 dd (9.4, 4.6) 73.3 CH 3.90 d (7.5) 73.2 CH
4 - 66.9 Cq - 70.6 Cq - 85.6 Cq - 83.9 Cq
5 - 44.5 Cq - 44 Cq - 50.2 Cq - 50.8 Cq
6 3.78 dd (8.1, 
7.7)
74.3 CH 3.78 dd (8.1, 7.7) 74.5 CH - 108.1 Cq - 110.9 Cq
7 - 30.8 CH2 1.65 m, 1.75 m 38.1 CH2 1.45 m,
2.2 m
41.2 CH2 1.65 t (10.1), 
2.36 dd (10.3, 3.9)
36.1 CH2
8 1.7 35.1 or 35.2 CH 1.94 m 35.4 CH 2.28 m 36.3 CH 1.86 m 35.2 CH
9 - 48 Cq - 43.5 Cq - 36.2 Cq - 44.6 Cq
10 1.7 m 47 CH 2.22 brd (14.9) 47.5 CH 2.23 m 43.9 CH 2.13 m 37.8 CH
11 1.4 m, 2.25 m 34.6 CH2 1.75 m 38.0 CH2 1.89 dd (12.2, 
9.6), 2.43 m
34.2 CH2 1.85 m, 
2.24 brdd (9,3)
40.5 CH2
12 2.15 m, 2.28 m 19.3 CH2 4.56 brt (7) 63.8 CH2 4.76 m 65.8 CH 5.10 m 71.6 CH
13 - 138.9 Cq - 144.1 Cq 3.1 m 49.7 CH - 126.7 Cq
14 7.02 d (2.2) 144.8 CH 7.13 brs 144.8 CH 14.2 m, 2.04 m 33 CH2 6.41 m 108.6 CH
15 5.84 d (1.9) 104.6 CH 5.88 brs 104.6 CH - 174.5 Cq 7.43 m 143.6 CH
16 - 173.3 Cq - 171.7 Cq - 173.1 Cq 7.43 m 139.3 CH
17 0.97 d (6.0) 16.5 CH3 1.00 (6.7) 16.7 CH3 0.94 br 16.4 CH3 1.02 d (6.0) 16.3 CH3
18 3.21 d (3.8), 
3.01 d (3.8)
42 CH2 2.98 d (4.2), 
3.17 d (3.9)
43 CH2 3.97 d (10.5), 
4.34 d (10.5)
75.6 CH2 3.89 d (7.5),
4.42 d (7.7)
75.1 CH2
19 4.65 d (12.2), 
4.43 d (12.2)
63.7 CH2 4.12 d (13.5), 4.71 d (13.5) 63.9 CH2 4.59 d (12.3), 
4.65 d (12.3)
68.5 CH2 3.94 d (9.1), 
4.15 d (9.1)
58.5 CH2
20 3.97 d (12.0), 
4.03 d (12.0)
66.5 CH2 3.89 d (13.5, 0.5 H), 3.90 d 
(13.5, 0.5 H), 3.94 d (13.5, 0.5 
H), 3.95 d (13.5, 0.5 H)
66.64 or 
66.55 CH2
- 174.5 Cq 5.08 s 101.1 CH
MeCO2-19 2.06 s 20.98 or 21.03 
CH3
2.02 s 21.0 CH3
MeCO2-19 172.7 Cq - 172.8 Cq
MeCO2-20 2.06 s 20.98 or 21.03 
CH3
2.01 s 21.0 CH3
MeCO2-20 172.7 Cq - 172.5 Cq
MeO-6 3.37 s 48.1 CH3
MeO-15 3.52 s 57.3 CH3 3.54 s (1.5 H), 3.55 s (1.5 H) 57.4 CH3
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Table S4. 1H and 13C NMR data for 12-14.
12 (CD3OD) 13 ((CD3)2SO) 14 ((CD3)2SO) 14 (CDCl3)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.78 m, 2.12 m 23.1 CH2 1.86 m, 1.98 m 24.3 CH2 1.75 m, 2.05 m 21.5 CH2 1.92 brd (10.5), 
2.15 m
40.1 CH2
2 1.45 m, 2.22 m 34.1 CH2 1.27 m, 1.87 m 31.6 CH2 1.17 dd (11, 4), 
1.91 m
43.5 CH2 1.31 dq (4.5, 12.0), 
2.18 m
32.9 CH2
3 4.28 m 68.6 CH - 57.7 Cq 3.80 brd (11) 65.0 CH 4.02 dd (12.0, 4.5) 66.0 CH
4 - 52.8 Cq 3.66 dd (11, 4), 
3.27 dd (11, 5)
62.5 CH2 - 70.0 Cq - nd
5 - 48.0 Cq - 59.3 Cq - 45.5 Cq - nd
6 4.99 m 74.7 CH 3.36 dd  (11, 4) 69.4 CH 3.62 brd (11) 73.3 CH 3.70 dd (10.0, 6.0) 73.6 CH
7 1.56 m, 2.22 m 33.5 CH2 1.21 q (11), 1.47 m 37.9 CH2 1.39 brd (12), 
1.52 brq (12)
34.7 CH2 1.65 m 34.0 CH2
8 1.78 m 38.7 CH 1.47 m 35.6 CH 1.68 m 34 CH 1.73 m 35.6 CH
9 - 52.0 Cq - 40.4 Cq - 43.3 Cq - nd
10 1.89 m 51.8 CH 2.07 dd (12, 5) 51.5 CH 1.96 brd (11) 46.8 CH 2.02 dd (13.0, 2.5) 48.3 CH
11 2.38 m, 2.51 m 43.6 CH2 1.60 dd (16, 4), 
2.01 dd 16, 9)
41.7 CH2 1.67 m, 1.86 m 39.7 CH2 1.80 dd (16.0, 2.0), 
2.17 m
32.9 CH2
12 5.48 m 73.5 CH 4.68 m 62.1 CH 4.59 m 61.7 CH 4.86 brd (8.5) 63.3 CH
13 - 126.7 Cq - 132.4 Cq - 132.8 Cq - nd
14 6.46 m 109.17 CH 6.46 m 109.7 CH 6.42 m 109.6 CH 6.41 m 108 CH
15 7.53 m 145.6 CH 7.56 m 143.5 CH 7.56 m 143.6 CH 7.39 m 138 CH
16 7.59 m 141.4 CH 7.50 m 143.5 CH 7.49 m 138.6 CH 7.39 m 138 CH
17 0.99 m 16.9 CH3 0.71 d (7) 16.3 CH3 0.82 d (6) 17.0 CH3 0.93 d (6.5) 17.0 CH3
18 2.72 br, 2.82 br 42.5 CH2 4.76 d (7) 102.0 CH 2.83 m, 3.06 m 43.0 CH2 3.03 d (4.0), 
3.13 d (3.5)
43.5 CH2
19 3.90 d (9.4), 4.62 d 
(9.3)
61.4 CH2 3.80 d (9), 3.87 d 
(9)
67.3 CH 4.40 d (12), 
4.57 d (12)
62.4 CH2 4.48 d (12.0), 
4.68 d (12.0)
62.5 CH2
20 - 178.9 Cq 3.21 dd (11, 5), 
3.32 dd (11, 5)
63.3 CH2 3.28 m 63.0 CH2 3.59 s (2 H) 64.3 CH2
MeCO2-6 2.04 s 21.3 CH3
MeCO2-6 171.6 Cq
HO-3 4.68 br - nd
HO-4 4.46 m -
HO-6 4.46 m - 3.28 m - nd
HO-12 5.02 d (5) - 4.90 br - nd
HO-18 6.26 d (7) -
HO-20 4.46 m - 4.90 br - nd
13
Table S5. 1H and 13C NMR data for 15,16. nd = not observed
15 ((CD3)2SO) 15 (CDCl3) 16 ((CD3)2SO) 16 (CDCl3)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.59 brq (12), 
1.96 m
22.0 CH2 1.83 dq (4.5, 13.0), 
1.95 m
22.1 CH2 1.43 m, 
1.68 brd (12)
21.5 CH2 1.70 m (2 H) 21.5 CH2
2 1.30 dq (4, 12), 
2.05 m
34.1 CH2 1.40 dq (5.0, 12.5), 
2.30 m
32.5 CH2 1.20 dq (11, 4), 
2.00 m
34.1 CH2 1.30 dd (14.0, 8.0), 
2.26 m
32.2 CH2
3 4.19 m 64.3 CH 4.43 ddd (13.0, 5.0, 
2.0)
64.8 CH 4.16 t (10,4) 64.5 CH 4.47 ddd (10.0, 5.0, 
3.5)
65.1 CH
4 - 68.8 Cq - nd - 68.8 Cq - nd
5 - 46.4 Cq - nd 46.2 Cq - nd
6 3.67 m 72.5 CH 3.73 dd (12.0, 4.0) 73.9 CH 3.65 m 72.5 CH 3.75 dd (13.5, 3.5) 74.3 CH
7 1.48 brd (12), 
1.96 m
34.9 CH2 1.69 dt (13.0, 4.0), 
2.17 q (12.5)
33.4 CH2 1.43 m, 1.74 m 35.6 CH2 1.65 dt (13.0, 3.5), 
2.08 brq (12.0)
33.6 CH2
8 1.62 m 37.3 CH 1.58 m 38.3 CH 1.74 m 40.0 CH 1.70 m 41.1 CH
9 - 51.5 Cq - nd - 51.5 Cq - nd
10 1.67 brd (12) 51.2 CH 1.60 dd (13.0, 3.0) 52.1 CH 1.50 brd (12) 49.2 CH 1.45 dd (12.0, 4.0) 49.8 CH
11 2.25 dd (10, 7), 
2.45 dd (10, 7)
41.2 CH2 2.34 d (8.5) nd 2.33 dd (11, 7), 
2.41 dd (11, 7)
42.6 CH2 2.32 dd (14.0, 8.0), 
2.42 m
43.8 CH2
12 5.43 t (7) 71.4 CH 5.34 t (8.5) 71.5 CH 5.42 t (7) 71.3 CH 5.36 t (8.5) 71.3 CH
13 - 125.6 Cq - nd - 125.8 Cq - nd
14 6.49 m 109.1 CH 6.36 m 107 CH 6.51 m 109.3 CH 6.35 m 107.5 CH
15 7.74 m 145.0 CH 7.42 m 143 CH 7.71 m 145.0 CH 7.45 m 139 CH
16 7.78 m 141.1 CH 7.42 m 139 CH 7.77 m 140.7 CH 7.43 m 139 m
17 0.91 d (6) 16.9 CH3 1.01 d (7.0) 16.5 CH3 1.00 d (6) 17.3 CH3 1.13 d (7.0) 17.0 CH3
18 2.69 d (4), 
2.89 d (4)
40.6 CH2 2.99 d (4.0), 
3.01 d (4.0)
42.2 CH2 2.65 d (4), 
2.83 d (4)
40.9 CH2 2.97 d (4.0), 
3.00 d (3.5)
42.4 CH2
19 3.69 m, 4.36 m 59.3 CH2 3.88 dd (12.5, 10.0), 
4.73 (12.5, 3.5)
60.7 CH2 3.76 dd (11, 8), 
4.40 dd (11, 2)
60.1 CH2 4.00 dd (13.5, 11.0), 
4.76 dd (13.5, 4.0)
61.5 CH2
20 - 177.0 Cq - nd - 176.8 Cq - nd
HO-3 4.66 d (4) 2.82 br 4.60 d (4) 2.12 d (5.0)
HO-6 3.99 br 4.03 brd (7) nd
HO-19 4.07 m 2.69 dd  (10.0, 3.5) 4.10 brd (8) 2.42 m
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Table S6. 1H and 13C NMR data for 17,18. nd = not observed
17 ((CD3)2SO) 17 (CDCl3) 18 ((CD3)2SO) 18 (CDCl3)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz) dC type dH mult. (J Hz)
1 1.95 m, 2.0 m 22.6 CH2 1.91 m, 2.12 m 22 CH2 1.25 brq (12), 2.27 m 71.6 CH2 1.13 m, 2.22 m
2 1.80 m, 2.45 m 36 CH2 1.50 dd (12.5, 5.0) 28 CH2 1.39 dq (3, 12) 33.0 CH2 1.4 m
3 5.45 m 71.4 CH 5.54 dd (12.5, 5.0) 55 CH 4.06 m 51.5 CH 4.44 m
4 - 76.9 Cq - nd - 139.5 Cq -
5 - 48.2 Cq - nd - 137.4 Cq -
6 4.20 brd (11) 72.8 CH 4.21 brd (11.0) 54 CH - 109.16 Cq -
7 1.54 m, 1.87 brq (11) 36.1 CH2 1.70 m, 2.20 brq (12.5) 35 CH2 1.82 dd (13, 3), 2.27 t (13) 39.6 CH2 1.99 dd (13.5, 4.0), 2.22 m
8 1.70 m 37.7 CH 1.70 m 39 CH 2.01 m 35.8 CH 2.09 m
9 - 51.7 Cq - 51 Cq - 53.0 Cq -
10 1.80 m 42.6 CH 1.87 m 49 CH 2.45 m 40 CH 2.48 m
11 2.32 dd (12, 9), 2.45 m 43.1 CH2 2.40 d (8.5) 44 CH2 2.42 dd (12, 8), 2.57 dd 
(12, 8)
40 CH2 2.48 m
12 5.45 m 74.0 CH 5.35 t (8.5) 71 CH 5.48 t (8) 71.6 CH 5.38 t (8.5)
13 - 125.7 Cq - 124 Cq - 125.4 Cq -
14 6.51 m 109.1 CH 6.38 m 109 CH 6.52 m 109.20 CH 6.39 m
15 7.71 m 144.9 CH 7.44 m 143 CH 7.72 t (3) 145.0 7.45 m
16 7.79 m 141.2 CH 7.44 m 139 CH 7.82 m 141.2 7.45 m
17 0.96 d (6) 16.8 CH3 1.06 d (7.5) 17 CH3 0.92 d (7) 17.2 CH3 0.99 d (6.5)
18 3.43 dd (10, 3),
4.04 dd (10, 5)
61.1 CH2 4.04 brd (12.0),
4.09 brd (12.0)
60.5 CH2 6.02 s 107.0 CH 6.21 s
19 4.77 d (12), 4.86 d (12) 63.9 (CH2) 5.06 d (13.0), 5.08 d (13.0) 63 CH2
20 - 177.1 Cq - nd - 176.6 Cq -
MeCO2-3 2.05 s 21.6 CH3 2.11 s 21 CH3
MeCO2-3 - 170.4 Cq - 170 Cq
MeCO2-19 2.00 s 21.8 CH3 2.10 s 21 CH3
MeCO2-19 - 169.9 Cq - 170 Cq
HO-3 5.06 d (7) nd
HO-4 4.39 br nd
HO-6 5.06 m nd
HO-18 5.06 m nd
MeO-6 2.97 s 49.0 CH3 3.11 s
MeO-18 3.15 s 51.5 CH3 3.39 s
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Table S7. 1H and 13C NMR data for 19,20.
19 ((CD3)2SO) 20 ((CD3)2SO)
Position dH mult. (J Hz) dC type dH mult. (J Hz) dC type
1 1.50 m, 1.66 dq (4,11) 20.0 CH2 1.49 m, 1.65 dq (4,11) 20.0 CH2
2 1.24 m, 1.55 m 34.42 CH2 1.20 dq (4,11), 1.51 m 34.1 CH2
3 3.82 m 64.5 CH 4.10 m 64.7 CH
4 - 69.6 Cq - 69.4 Cq
5 - 45.2 Cq - 46.9 Cq
6 3.63 dd, 12, 3) 72.7 CH 3.55 dd (12, 6) 72.8 CH
7 1.43 m, 1.50 m 34.41 CH2 1.45 m, 1.51 m 34.1 CH2
8 1.24 m 34.1 CH 1.44 m 34.2 CH
9 - 38.6 Cq - 38.5 Cq
10 1.38 m 46.3 CH 1.25 dd (11, 3) 46.5 CH
11 1.50 m, 1.98 m 34.38 CH2 1.45 m, 1.97 m 34.2 CH2
12 2.15 ddd (11, 9, 4), 2.25 ddd (11, 9, 3) 21.9 CH2 2.12 ddd (11, 9, 4), 2.25 ddd (11, 9, 3) 22.0 CH2
13 - 174.4 Cq - 174.4 Cq
14 5.96 br 114.0 CH 5.95 s 113.9 CH
15 - 173.4 Cq - 173.5 Cq
16 4.86 s 73.5 CH2 4.86 s 73.5 CH2
17 0.78 d (7) 15.8 CH3 0.77 d (7) 15.9 CH3
18 2.84 d (4), 3.09 d (4) 43.0 CH2 2.70 d (4), 2.89 d (4) 40.5 CH2
19 4.34 d (11), 4.49 d (11) 62.4 CH2 3.78 dd (11, 9), 3.98 dd (11, 3) 60.3 CH2
20 0.65 s 17.6 CH3 0.62 s 17.7 CH3
MeCO2-19 2.02 s 21.5 CH3
MeCO2-19 - 170.8 Cq
HO-3 4.76 d (5) - 4.56 d (4) -
HO-6 nd - 3.82 m -
HO-19 - - 4.12 dd (9, 3) -
Figure S1. 1H NMR spectrum of 1 in CD3OD.
16
Figure S2. Expansion of part of 1H NMR spectrum (d 1.0 – d 2.7) of 1 in CD3OD.
17
Figure S3. Expansion of part of 1H NMR spectrum (d 3.7 – d 5.6) of 1 in CD3OD.
18
Figure S4. 1H NMR spectrum of 1 in (CD3)2SO.
19
Figure S5. 13C NMR spectrum of 1 in CD3OD.
20
Figure S6. COSY NMR spectrum of 1 in CD3OD.
21
Figure S7. HSQC NMR spectrum of 1 in CD3OD.
22
Figure S8. HMBC NMR spectrum of 1 in CD3OD.
23
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Figure S9. Positive-ion HRESIMS of 1.
24
Figure S10. 1H NMR spectrum of 2 in CD3OD.
25
Figure S11. Expansion of part of 1H NMR spectrum (d 0.9 – d 3.3) of 2 in CD3OD.
26
Figure S12. Expansion of part of 1H NMR spectrum (d 3.9 – d 5.6) of 2 in CD3OD.
27
Figure S13. 13C NMR spectrum of 2 in CD3OD.
28
Figure S14. COSY NMR spectrum of 2 in CD3OD.
29
Figure S15. HSQC NMR spectrum of 2 in CD3OD.
30
Figure S16. HMBC NMR spectrum of 2 in CD3OD.
31
R12 #286-310 RT: 4.09-4.40 AV: 12 NL: 1.09E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]
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Figure S17. Positive-ion HRESIMS of 2.
32
Figure S18. 1H NMR spectrum of 3 in CD3OD.
33
Figure S19. Expansion of part of 1H NMR spectrum (d 0.6 – d 2.6) of 3 in CD3OD.
34
Figure S20. Expansion of part of 1H NMR spectrum (d 3.75 – d 4.95) of 3 in CD3OD.
35
Figure S21. 13C NMR spectrum of 3 in CD3OD.
36
Figure S22. COSY NMR spectrum of 3 in CD3OD.
37
Figure S23. NOESY NMR spectrum of 3 in CD3OD.
38
Figure S24. HSQC NMR spectrum of 3 in CD3OD.
39
Figure S25. HMBC NMR spectrum of 3 in CD3OD.
40
Figure S26. Positive-ion HRESIMS of 3.
41
56843-8 #122-369 RT: 1.71-5.00 AV: 248 NL: 7.78E6
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Figure S27. Negative-ion HRESIMS of 3.
42
Figure S28. 1H NMR spectrum of 4 in CD3OD.
43
Figure S29. Expansion of part of 1H NMR spectrum (d 0.5 – d 3.0) of 4 in CD3OD.
44
Figure S30. Expansion of part of 1H NMR spectrum (d 4.3 – d 7.7) of 4 in CD3OD.
45
Figure S31. 13C NMR spectrum of 4 in CD3OD / CDCl3.
46
Figure S32. COSY NMR spectrum of 4 in CD3OD.
47
Figure S33. NOESY NMR spectrum of 4 in CD3OD.
48
Figure S34. HSQC NMR spectrum of 4 in CD3OD.
49
Figure S35. HMBC NMR spectrum of 4 in CD3OD.
50
Figure S36. Positive-ion HRESIMS of 4.
51
Figure S37. 1H NMR spectrum of 5 in CD3OD.
52
Figure S38. Expansion of part of 1H NMR spectrum (d 0.9 – d 3.0) of 5 in CD3OD.
53
Figure S39. Expansion of part of 1H NMR spectrum (d 5.3 – d 7.9) of 5 in CD3OD.
54
Figure S40. 13C NMR spectrum of 5 in CD3OD.
55
Figure S41. COSY NMR spectrum of 5 in CD3OD.
56
Figure S42. HSQC NMR spectrum of 5 in CD3OD.
57
Figure S43. HMBC NMR spectrum of 5 in CD3OD.
58
Figure S44. Positive-ion HRESIMS of 5.
59
Figure S45. 1H NMR spectrum of 6 in CD3OD.
60
Figure S46. Expansion of part of 1H NMR spectrum (d 0.7 – d 3.4) of 6 in CD3OD.
61
Figure S47. Expansion of part of 1H NMR spectrum (d 4.3 – d 7.7) of 6 in CD3OD.
62
Figure S48. 13C NMR spectrum of 6 in CD3OD.
63
Figure S49. COSY NMR spectrum of 6 in CD3OD.
64
Figure S50. HSQC NMR spectrum of 6 in CD3OD.
65
Figure S51. HMBC NMR spectrum of 6 in CD3OD.
66
Figure S52. Positive-ion HRESIMS of 6.
5363B35 #183-328 RT: 2.57-4.56 AV: 146 NL: 2.53E6
T: FTMS + p ESI Full ms [100.0000-2000.0000]

































Figure S53. 1H NMR spectrum of 7 in CD3OD.
68
Figure S54. Expansion of part of 1H NMR spectrum (d 0.7 – d 2.8) of 7 in CD3OD.
69
Figure S55. Expansion of part of 1H NMR spectrum (d 3.7 – d 7.4) of 7 in CD3OD.
70
Figure S56. 13C NMR spectrum of 7 in CD3OD.
71
Figure S57. COSY NMR spectrum of 7 in CD3OD.
72
Figure S58. NOESY NMR spectrum of 7 in CD3OD.
73
Figure S59. HSQC NMR spectrum of 7 in CD3OD.
74
Figure S60. HMBC NMR spectrum of 7 in CD3OD.
75
Figure S61. Negative-ion HRESIMS of 7.
76
Figure S62. 1H NMR spectrum of 8 in CD3OD.
77
Figure S63. Expansion of part of 1H NMR spectrum (d 0.4 – d 2.6) of 8 in CD3OD.
78
Figure S64. Expansion of part of 1H NMR spectrum (d 2.9 – d 4.7) of 8 in CD3OD.
79
Figure S65. 13C NMR spectrum of 8 in CD3OD.
80
Figure S66. COSY NMR spectrum of 8 in CD3OD.
81
Figure S67. NOESY NMR spectrum of 8 in CD3OD.
82
Figure S68. HSQC NMR spectrum of 8 in CD3OD.
83
Figure S69. HMBC NMR spectrum of 8 in CD3OD.
84
Figure S70. Positive-ion HRESIMS of 8.
85
Figure S71. 1H NMR spectrum of 9 in CD3OD.
86
Figure S72. Expansion of part of 1H NMR spectrum (d 0.4 – d 2.6) of 9 in CD3OD.
87
Figure S73. Expansion of part of 1H NMR spectrum (d 2.9 – d 4.8) of 9 in CD3OD.
88
Figure S74. 13C NMR spectrum of 9 in CD3OD.
89
Figure S75. COSY NMR spectrum of 9 in CD3OD.
90
Figure S76. NOESY NMR spectrum of 9 in CD3OD.
91
Figure S77. HSQC NMR spectrum of 9 in CD3OD.
92
Figure S78. HMBC NMR spectrum of 9 in CD3OD.
93
Figure S79. Positive-ion HRESIMS of 9.
94
Figure S80. 1H NMR spectrum of 10 in CD3OD.
95
Figure S81. Expansion of part of 1H NMR spectrum (d 0.6 – d 2.7) of 10 in CD3OD.
96
Figure S82. Expansion of part of 1H NMR spectrum (d 3.5 – d 4.7) of 10 in CD3OD.
97
Figure S83. 13C NMR spectrum of 10 in CD3OD.
98
Figure S84. COSY NMR spectrum of 10 in CD3OD.
99
Figure S85. HSQC NMR spectrum of 10 in CD3OD.
100
Figure S86. HMBC NMR spectrum of 10 in CD3OD.
101
Figure S87. Positive-ion and negative-ion HRESIMS of 10.
102
Figure S88. 1H NMR spectrum of 11 in CD3OD.
103
Figure S89. Expansion of part of 1H NMR spectrum (d 0.2 – d 2.6) of 11 in CD3OD.
104
Figure S90. Expansion of part of 1H NMR spectrum (d 3.4 – d 7.5) of 11 in CD3OD.
105
Figure S91. 13C NMR spectrum of 11 in CD3OD.
106
Figure S92. COSY NMR spectrum of 11 in CD3OD.
107
Figure S93. NOESY NMR spectrum of 11 in CD3OD.
108
Figure S94. HSQC NMR spectrum of 11 in CD3OD.
109
Figure S95. HMBC NMR spectrum of 11 in CD3OD.
110
Figure S96. 1H NMR spectrum of 12 in CD3OD.
111
Figure S97. Expansion of part of 1H NMR spectrum (d 0.6 – d 2.9) of 12 in CD3OD.
112
Figure S98. Expansion of part of 1H NMR spectrum (d 3.6 – d 7.8) of 12 in CD3OD.
113
Figure S99. 13C NMR spectrum of 12 in CD3OD.
114
Figure S100. COSY NMR spectrum of 12 in CD3OD.
115
Figure S101. NOESY NMR spectrum of 12 in CD3OD.
116
Figure S102. HSQC NMR spectrum of 12 in CD3OD.
117
Figure S103. HMBC NMR spectrum of 12 in CD3OD.
118
Figure S104. Positive-ion HRESIMS of 12.
119
Figure S105. 1H NMR spectrum of 13 in (CD3)2SO.
120
Figure S106. Expansion of part of 1H NMR spectrum (d 0.9 – d 5.1) of 13 in (CD3)2SO.
121
Figure S107. 13C NMR spectrum of 13 in (CD3)2SO.
122
Figure S108. 135DEPT NMR spectrum of 13 in (CD3)2SO.
123
Figure S109. COSY NMR spectrum of 13 in (CD3)2SO.
124
Figure S110. HSQC NMR spectrum of 13 in (CD3)2SO.
125
Figure S111. HMBC NMR spectrum of 13 in (CD3)2SO.
126
R13 #232-252 RT: 3.34-3.58 AV: 10 NL: 1.43E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]




















































Figure S112. Positive-ion HRESIMS of 13.
127
Figure S113. Negative-ion HRESIMS of 13.
R13 #232-252 RT: 3.32-3.60 AV: 11 NL: 7.33E6
F: FTMS - p ESI Full ms [100.0000-2000.0000]
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128
Figure S114. 1H NMR spectrum of 14 in CDCl3.
129
Figure S115. Expansion of part of 1H NMR spectrum (d 0.7 – d 2.5) of 14 in CDCl3.
130
Figure S116. Expansion of part of 1H NMR spectrum (d 2.8 – d 5.2) of 14 in CDCl3.
131
Figure S117. Expansion of part of 1H NMR spectrum (d 6.2 – d 7.7) of 14 in CDCl3.
132
Figure S118. 13C NMR spectrum of 14 in (CD3)2SO.
133
Figure S119. 135DEPT NMR spectrum of 14 in (CD3)2SO.
134
Figure S120. COSY 1H NMR spectrum of 14 in CDCl3.
135
Figure S121. HSQC NMR spectrum of 14 in (CD3)2SO.
136
Figure S122. HSQC 1H NMR spectrum of 14 in CDCl3.
137
Figure S123. Expansion of part of HSQC NMR spectrum (d 0.7 – d 2.5) of 14 in CDCl3.
138
Figure S124. Expansion of part of HSQC NMR spectrum (d 3.0 – d 4.9) of 14 in CDCl3.
139
Figure S125. HMBC NMR spectrum of 14 in (CD3)2SO.
140
R3 #249-261 RT: 3.56-3.73 AV: 7 NL: 3.20E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]
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Figure S126. Positive-ion HRESIMS of 14.
141
Figure S127. Negative-ion HRESIMS of 14.
R3 #249-261 RT: 3.58-3.72 AV: 6 NL: 1.29E7
F: FTMS - p ESI Full ms [100.0000-2000.0000]
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142
Figure S128. 1H NMR spectrum of 15 in (CD3)2SO.
143
Figure S129. Expansion of part of 1H NMR spectrum (d 0.8 – d 3.2) of 15 in (CD3)2SO.
144
Figure S130. Expansion of part of 1H NMR spectrum (d 3.1 – d 5.5) of 15 in (CD3)2SO.
145
Figure S131. 1H NMR spectrum of 15 in CDCl3.
146
Figure S132. Expansion of part of 1H NMR spectrum (d 0.8 – d 3.2) of 15 in CDCl3.
147
Figure S133. Expansion of part of 1H NMR spectrum (d 3.3 – d 5.6) of 15 in CDCl3.
148
Figure S134. Expansion of part of 1H NMR spectrum (d 5.8 – d 7.8) of 15 in CDCl3.
149
Figure S135. 13C NMR spectrum of 15 in (CD3)2SO.
150
Figure S136. 135DEPT NMR spectrum of 15 in (CD3)2SO.
151
Figure S137. COSY NMR spectrum of 15 in CDCl3.
152
Figure S138. Expansion of part of COSY NMR spectrum of 15 in CDCl3.
153
Figure S139. NOESY NMR spectrum of 15 in (CD3)2SO.
154
Figure S140. HSQC NMR spectrum of 15 in (CD3)2SO.
155
Figure S141. HSQC NMR spectrum of 15 in CDCl3.
156
Figure S142. Expansion of part of HSQC NMR spectrum (d 0.7 – d 3.2) of 15 in CDCl3.
157
Figure S143. Expansion of part of HSQC NMR spectrum (d 2.9 – d 5.5) of 15 in CDCl3.
158
Figure S144. HMBC NMR spectrum of 15 in (CD3)2SO.
159
Figure S145. Positive-ion HRESIMS of 15.
R6 #265-290 RT: 3.79-4.13 AV: 13 NL: 1.99E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]






















































Figure S146. Negative-ion HRESIMS of 15.
R6 #265-290 RT: 3.80-4.14 AV: 13 NL: 1.49E6
F: FTMS - p ESI Full ms [100.0000-2000.0000]
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161
Figure S147. 1H NMR spectrum of 16 in (CD3)2SO.
162
Figure S148. Expansion of part of 1H NMR spectrum (d 0.9 – d 3.2) of 16 in (CD3)2SO.
163
Figure S149. Expansion of part of 1H NMR spectrum (d 3.6 – d 5.5) of 16 in (CD3)2SO.
164
Figure S150. 1H NMR spectrum of 16 in CDCl3.
165
Figure S151. Expansion of part of 1H NMR spectrum (d 0.7 – d 3.5) of 16 in CDCl3.
166
Figure S157. Expansion of part of 1H NMR spectrum (d 3.7 – d 7.9) of 16 in CDCl3.
167
Figure S153. 13C NMR spectrum of 16 in (CD3)2SO.
168
Figure S154. 135DEPT NMR spectrum of 16 in (CD3)2SO.
169
Figure S155. COSY NMR spectrum of 16 in (CD3)2SO.
170
Figure S156. COSY NMR spectrum of 16 in CDCl3.
171
Figure S157. Expansion of part of COSY NMR spectrum (d 0.9 – d 5.5) of 16 in CDCl3.
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Figure S158. NOESY NMR spectrum of 16 in (CD3)2SO.
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Figure S159. HSQC NMR spectrum of 16 in (CD3)2SO.
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Figure S160. HSQC NMR spectrum of 16 in CDCl3.
175
Figure S161. Expansion of part of HSQC NMR spectrum (d 1.0 – d 3.1) of 16 in CDCl3.
176
Figure S162. Expansion of part of HSQC NMR spectrum (d 2.9 – d 5.4) of 16 in CDCl3.
177
Figure S163. HMBC NMR spectrum of 16 in (CD3)2SO.
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R7 #235-299 RT: 3.36-4.25 AV: 33 NL: 1.18E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]
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Figure S164. Positive-ion HRESIMS of 16.
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Figure S165. 1H NMR spectrum of 17 in (CD3)2SO.
180
Figure S166. Expansion of part of 1H NMR spectrum (d 0.9 – d 2.8) of 17 in (CD3)2SO.
181
Figure S167. Expansion of part of 1H NMR spectrum (d 3.6 – d 5.5) of 17 in (CD3)2SO.
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Figure S168. 1H NMR spectrum of 17 in CDCl3.
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Figure S169. Expansion of part of 1H NMR spectrum (d 0.7 – d 3.2) of 17 in CDCl3.
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Figure S170. Expansion of part of 1H NMR spectrum (d 2.8 – d 5.8) of 17 in CDCl3.
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Figure S171. Expansion of part of 1H NMR spectrum (d 6.0 – d 7.7) of 17 in CDCl3.
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Figure S172. 13C NMR spectrum of 17 in (CD3)2SO.
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Figure S173. 135DEPT NMR spectrum of 17 in (CD3)2SO.
188
Figure S174. COSY NMR spectrum of 17 in (CD3)2SO.
189
Figure S175. COSY NMR spectrum of 17 in CDCl3.
190
Figure S176. Expansion of part of COSY NMR spectrum (d 0.5 – d 5.5) of 17 in CDCl3.
191
Figure S177. HSQC NMR spectrum of 17 in (CD3)2SO.
192
Figure S178. HSQC NMR spectrum of 17 in CDCl3.
193
Figure S179. Expansion of part of HSQC NMR spectrum (d 0.8 – d 2.7) of 17 in CDCl3.
194
Figure S180. Expansion of part of HSQC NMR spectrum (d 3.6 – d 5.6) of 17 in CDCl3.
195
Figure S181. HMBC NMR spectrum of 17 in (CD3)2SO.
196
Figure S182. Positive-ion HRESIMS of 17.
R1 #301-322 RT: 4.32-4.60 AV: 11 NL: 2.71E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]
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Figure S183. Negative-ion HRESIMS of 17.
R1 #301-322 RT: 4.34-4.61 AV: 11 NL: 6.35E6
F: FTMS - p ESI Full ms [100.0000-2000.0000]
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Figure S184. 1H NMR spectrum of 18 in (CD3)2SO.
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Figure S185. Expansion of part of 1H NMR spectrum (d 0.9 – d 2.7) of 18 in (CD3)2SO.
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Figure S186. 1H NMR spectrum of 18 in CDCl3.
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Figure S187. Expansion of part of 1H NMR spectrum (d 0.8 – d 3.7) of 18 in CDCl3.
202
Figure S188. Expansion of part of 1H NMR spectrum (d 3.0 – d 7.8) of 18 in CDCl3.
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Figure S189. 13C NMR spectrum of 18 in (CD3)2SO.
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Figure S190. 135DEPT NMR spectrum of 18 in (CD3)2SO.
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Figure S191. COSY NMR spectrum of 18 in (CD3)2SO.
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Figure S192. HSQC NMR spectrum of 18 in (CD3)2SO.
207
Figure S193. HMBC NMR spectrum of 18 in (CD3)2SO.
208
R2 #304-333 RT: 4.37-4.77 AV: 15 NL: 1.06E7
F: FTMS + p ESI Full ms [100.0000-2000.0000]















































227.0815 265.1222 775.2940445.1198 835.3149515.0890 739.2727610.1842 891.3414639.2314 684.2031567.1604
Figure S194. Positive-ion HRESIMS of 18.
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Figure S195. 1H NMR spectrum of 19 in (CD3)2SO.
210
Figure S196. Expansion of part of 1H NMR spectrum (d 0.75 – d 2.3) of 19 in (CD3)2SO.
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Figure S197. 13C NMR spectrum of 19 in (CD3)2SO.
212
Figure S198. 135DEPT NMR spectrum of 19 in (CD3)2SO.
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Figure S199. HSQC NMR spectrum of 19 in (CD3)2SO.
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Figure S200. HMBC NMR spectrum of 19 in (CD3)2SO.
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Figure S201. 1H NMR spectrum of 20 in (CD3)2SO.
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Figure S202. Expansion of part of 1H NMR spectrum (d 0.6 – d 2.3) of 20 in (CD3)2SO.
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Figure S203. Expansion of part of 1H NMR spectrum (d 2.5 – d 4.2) of 20 in (CD3)2SO.
218
Figure S204. 13C NMR spectrum of 20 in (CD3)2SO.
219
Figure S205. 135DEPT NMR spectrum of 20 in (CD3)2SO.
220
Figure S206. HSQC NMR spectrum of 20 in (CD3)2SO.
221
Figure S207. HMBC NMR spectrum of 20 in (CD3)2SO.
222
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Teucrium yemense (dried aerial part, 1.6 Kg)
MeOH extract (388.6 g)
Defatted with hexane and extracted with MeOH
Suspended in distilled water and extracted with EtOAc followed by BuOH
EtOAc extract (49.6 g) BuOH extract (43.0 g) Part remaining in water































Cpd 3 Cpds 5,9 Cpd 8 Cpd 12 Cpds 1,7 Cpd 2 Cpds 4,6 Cpd 15 Cpd 19 Cpd 18 Cpds 11,13 Cpds 14,17 Cpd 10 Cpd 20 Cpd 16
Radial centrifugal thick-layer chromatography (Chromatotron) (CH2Cl2 / MeOH 19:1), followed by reverse-phase HPLC
Figure S208. Fractionation tree for isolation of compounds 1-20.
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General analytical and chromatographic procedures.
The 1D and 2D NMR experiments (1H, 13C, COSY, NOESY, HSQC and HMBC) were performed on Bruker Avance spectrometers (500 MHz or 400
MHz for 1H and 175 MHz for 13C NMR spectra), using the residual solvent signals as internal standards. Conventional pulse sequences were used
for COSY, NOESY, HSQC and HMBC. Coupling constants (J) are stated in Hz. Ultra-high accuracy mass analysis was done on a Nano-Flow linear
trap quadrupole Fourier Transformation Ion Cyclotron Resonance Mass Spectrometer Ultra (FT-ICR-MS) (“ultra” refers to the high-sensitivity ICR
cell) (Triversa Nanomate; Advion Biosciences Limited, Norfolk, UK). Samples were reconstituted in 70% aq. MeOH (100 mL). Samples were
vortexed and were centrifuged for 4 min at 13,000 rpm at 0C. Aliquots (20 mL) of supernatant was then transferred to a clean well on a 128-
well plate. The sample (13 mL) was injected by the nano-flow injection system, with an aliquot (5.0 mL) being delivered to the ICR cell. Gas
pressure was maintained at 0.5 psi with an applied voltage of 1.5 KV to maintain a consistent current of 60-120 nA. When operating in narrow
SIM mode, the resolution was 100,000 and the scan window 30 Da. Each scan was acquired in 60 sec. IR spectra were recorded on a Perkin-
Elmer FTIR 600 series spectrometer. Column chromatography was performed using normal-phase silica gel (Merck; 230-400 mm). HPLC was
performed on a Shimadzu system (Kyoto, Japan), consisting of two LC-6AD Semi-Preparative Solvent Delivery pumps coupled with Rheodyne
manual injector, communications bus module CBM-20A, a multi-wavelength photo-diode array detector (SPD-M20A), FRC-10A fraction
collector, all connected to a computer system with Intel Core DUO with Microsoft XP and Shimadzu’s LC solution software. It was fitted with two
columns, Shim-pack PREP-ODS (H) Kit (A) 250 mm × 4.6 mm i.d., 5 mm particles (B) 250 mm × 20 mm i.d., 5 mm. Analytical HPLC was
performed using the column under gradient conditions with a mobile phase consisting of MeCN and water programmed linearly to 100% MeCN
over 35 min at the flow rate 1.0 mL min-1. The UV detection wavelengths were 210 and 254 nm. The chromatographic separation HPLC was
performed using column and preparative HPLC conditions as for analytical HPLC, except the flow rate was 20 mL min-1.
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Assay for enhancement of insulin secretion.
Tolbutamide (TB), collagenase V and bovine serum albumin (BSA) were obtained from Sigma (St. Louis, MO, USA). The mouse ultrasensitive
insulin ELISA kit was purchased from Crystal Chem Inc. (IL, USA).
Isolation of murine pancreatic islets. Primary pancreatic islets were isolated from male BALB/c mice (28-36 g) from the ICCBS Animal Research
Facility. The animal handling and tissue harvesting were done in accordance with the requirements of the Institutional Animal Care and Use
Committee of ICCBS, University of Karachi, Pakistan. Pancreatic islets were isolated by digestion with collagenase V and islet-picking, as
described earlier.50,51 Mice were anaesthetized with sodium thiopental (30 mg Kg)-1 and the distended whole pancreas was digested at 37C in
collagenase solution (1.0 mg mL-1) for 15 min. The digested islets were further purified by centrifugation at 1000 rpm for 1 min, followed by
filtration using a pre-wetted 70 mm cell strainer. Islets were hand-picked with a siliconized Pasteur pipette under a NIKON SMZ-745
stereomicroscope. The isolation and purification medium used was Hank’s Balanced Salt Solution (HBSS) without Ca2+, Mg2+ and phenol red.
Assay. Freshly isolated islets (n = 3) of similar diameter (120−160 mm) were pre-incubated for 45 min at 37C in Krebs-Ringer bicarbonate (KRB)
buffer solution containing 0.1% BSA and glucose (3.0 mM) in Eppendorf tubes, and each condition was triplicated. Then islets were washed with
KRB buffer before transferred into KRB buffer (300 mL) containing glucose (16.7 mM), supplemented with either test compound (200 mM) or
tolbutamide (positive control) (200 mM) and incubated at 37C for 1 h. After incubation, an aliquot (200 mL) of the mixture was cooled to -40C
until it could be assayed for released insulin. The concentrations of insulin in the collected aliquots were measured using the mouse
ultrasensitive insulin ELISA kit according to the high-range protocol. The reading is the concentration of insulin in ng mL-1 of medium. After
calculation of the absolute amount of insulin in the medium, this amount was divided by three (the number of islets in the tube).
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